Request for quotation for the
Procurement of Kits for One Health
Project Rajasthan
Request for quotation (RFQ) number: RFQ # 2023-061
For: Procurement of Kits for One Health Project Rajasthan
Summary of deadlines
Release of RFQ 12 Dec 2023
Confirmation of interest due 14 Dec 2023
Quotations due 20 Dec 2023
Bidders notified of decision 30 Dec 2023
Note: PATH reserves the right to modify this schedule as needed. All parties will be notified
simultaneously by email of any changes.
1. PATH statement of business
PATH is a global nonprofit dedicated to a mission to advance health equity through innovation and
partnerships. With more than 40 years of experience forging multisector partnerships, and with expertise
in science, economics, technology, advocacy, and dozens of other specialties, PATH develops and
scales up innovative solutions to the world’s most pressing health challenges. Learn more at
www.path.org.
2
2. Purpose of the request for quotations
Deliverables: Supply of kits for diagnosis of brucellosis and leptospirosis in close contact of lab
confirmed cases both in Human and Animal.
Specifications: Below are the specifications of Kits for processing human samples for
diagnosis of Brucellosis and Leptospirosis:
KIT Specification
BRUCELLA IGG 1. For detection of IgG antibodies against Brucella in serum samples from
ELISA 96 test kit* 7 humans2. The kit should be suitable for surveillance and monitoring programs
kits or individual and herd diagnosis of Brucellosis.
3. The Kit should have CDSCO license for in vitro diagnostics application in
humans
4. The kit should contain Microwells coated with Brucella antigen (12x8),
Sample Diluent, Calibrator, Positive Control, Negative Control, Enzyme
conjugate, TMB Substrate, Stop Solution, Wash concentrate 20X.
BRUCELLA IGM 1. For detection of IgM antibodies against Brucella in serum samples from
ELISA 96 test kit* 7 humans.
kits 2. The kit should be suitable for surveillance and monitoring programs or
individual and herd diagnosis of Brucellosis.
3. The Kit should have CDSCO license for in vitro diagnostics application in
humans
4.The kit should contain Microwell coated with Brucella antigen (12x8) ,
Sample Diluent, Calibrator, Positive Control, Negative Control, Enzyme
conjugate, TMB Substrate, Stop Solution, Wash concentrate 20X.
LEPTOSPIROSIS
1. For detection of IgM antibodies against Leptospira in serum sample from
IGM ELISA 96 test
humans.
kit * 7 Kits
2. The kit should be suitable for surveillance and monitoring programs or
individual and herd diagnosis of Leptospirosis.
3. The Kit should have CDSCO license for in vitro diagnostics application in
humans
4.The kit should contain Leptospira Antigen-Coated Microwells - (12x8
wells).
5.The kit should contain consumables like Wash Buffer (20x) , Sample Diluent
,HRP Conjugated Anti-human IgM , TMB Chromogen (TMB).
6. For quality control each kit should contains Calibrator, Reactive control,
Negative Controls and Stop solution.
Note: Kit should have CDSCO license for in vitro diagnostics application in humans
* Specifications of Primer & Probes
Probes should be TaqMan MGB Probes dual-labelled probes that can be used in all of your real-
time and end-point PCR applications.
Should have various reporter dyes (FAM, VIC, NED) and synthesis scales.
3
Probes should be in liquid with fixed concentration.
Should have guaranteed yield of primer & probes.
A fixed Datasheet & Technical Report of each primer& Probe should be provided.
Company should offer technical support as & when needed.
Below are the specifications of kits for processing Animal Samples in diagnosis of Brucellosis
and Leptospirosis:
Kit Specifications
For detection of antibodies against Brucella spp. in serum samples from Cattle,
Goat, Sheep
BRUCELLA IGG For in-vitro Veterinary diagnostic use
ELISA The test should meet the requirements of the EU directive 64/432.
The kit should be suitable for surveillance and monitoring programs or individual
and herd diagnosis of Brucellosis.
The ELISA plate should be in strips of 8 wells.
For detection of antibodies against Brucella spp. in serum samples from Cattle,
Goat, Sheep
BRUCELLA IGM For in-vitro Veterinary diagnostic use
ELISA The test should meet the requirements of the EU directive 64/432.
The kit should be suitable for surveillance and monitoring programs or individual
and herd diagnosis of Brucellosis.
The ELISA plate should be in strips of 8 wells.
For detection of antibodies against Leptospira hardjo in serum sample from
Cattle
LEPTOSPIROSIS
For in-vitro Veterinary diagnostic use
IGM ELISA
The kit should be suitable for surveillance and monitoring programs or individual
and herd diagnosis of Leptospirosis.
The ELISA plate should be in strips of 8 wells.
Timeline:
Delivery of Kits (for Human) in SMS Medical College, Jaipur till 01st January 2024
Delivery of Kits (for Animal) in State Animal Husbandry Laboratory, Jaipur till 01st January 2024
4
3. Quotation requirements, pricing, and costs
Please insert your costs in the table below. The costs should be broken down into components and
include a full description of each component and its associated time and costs.
50% of advance payment will be done after issue of purchase order and rest after delivery of the product
to the assigned destination.
Line- Component/Item Component/Item Delivery date Unit cost Tax Amount Total line-item
item description [INR] cost [INR] –
no. Including
Taxes
1 BRUCELLA IGG ELISA 450 samples 08 January
(for processing animal 2024
samples)
2 BRUCELLA IGM ELISA 450 samples 08 January
(for processing animal 2024
samples)
3 LEPTOSPIROSIS IGM 450 samples 08 January
ELISA (for processing 2024
animal samples)
4 BRUCELLA IGG ELISA 7 kits 08 January
96 test kit (for processing 2024
human samples)
5 BRUCELLA IGM ELISA 7 kits 08 January
96 test kit (for processing 2024
human samples)
6 LEPTOSPIROSIS IGM 7 kits 08 January
ELISA 96 test kit (for 2024
processing human
samples)
7 BRUCELLA (for 08 January
processing human 2024
samples)
(10000pmol)- 2 units
8 BRUCELLA (for 08 January
processing human 2024
samples) (6000pmol) - 1 unit
9 BRUCELLA (for 08 January
processing human (Cat No.4387424) – 2 2024
samples) units
10 LEPTOSPIRA (for 08 January
processing human 2024
samples)
(10000pmol) - 2 units
11 LEPTOSPIRA (for (6000pmol) - 1 unit 08 January
processing human 2024
5
samples)
12 LEPTOSPIRA (for (Cat No.4387424) - 2 08 January
processing human units 2024
samples)
Quotation price
Note:
Indicate associated services for delivery of the supply, as applicable, including any user training,
maintenance costs for at least 12 months, warranties, testing, cost of deliverables/commodities,
shipping/freight, insurance, import taxes, any other associated costs, payment terms (if not standard;
that is, payment after delivery), or any other costs not listed.
The supplier is expected to submit a profile of corporate qualification, a summary of experience in
similar/related work carried out in the past 24 to 36 months, number of years in business, annual
revenue for the last three financial periods, clarification regarding which specific company legal entity
is bidding, and any other relevant justification for qualification.
By submitting a quotation, the supplier consents for PATH to carry out further due diligence,
responsibly and in line with relevant General Data Protection Regulation provisions.
4. Instructions for responding
A. PATH contacts
Technical and Financial proposals should be addressed to: Procurement Officer at
rfpindia@path.org
Technical Proposal should consist of: - Kits brochure with kit shelf life, specificity and sensitivity of kit,
CDSCO license.
Financial Proposal: -
The Financial Proposal should be provided in the format mentioned in point 3 of this RFP document i.e.,
Quotation requirements, pricing, and cost.
B. Confirmation of interest
Please send a statement acknowledging receipt of this solicitation and your intent to respond or not
respond no later than 14 December 2023. Send the confirmation to the contacts listed above.
C. Quotations due: 20 December 2023
6
Completed quotations should be submitted by email to the contacts listed above. The subject line of the
email should read: RFQ # 2023-061Your Company Name.
D. Conclusion of process
Applicants will be notified of PATH’s decision by 08 January 2024 Final award is subject to the terms and
conditions included in this solicitation, as well as successful final negotiations of all applicable terms and
conditions affecting this work.
5. Terms and conditions of the solicitation
A. Notice of nonbinding solicitation
PATH reserves the right to reject any and all bids received in response to this solicitation and is in no way
bound to accept any proposal.
B. Confidentiality
All information provided by PATH as part of this solicitation must be treated as confidential. In the event
that any information is inappropriately released, PATH will seek appropriate remedies as allowed.
Proposals, discussions, and all information received in response to this solicitation will be held as strictly
confidential, except as otherwise noted.
C. Conflict of interest disclosure
Suppliers bidding on PATH business must disclose, to the procurement contact listed in the RFP, any
actual or potential conflicts of interest. Conflicts of interest could include a personal relationship with a
PATH staff member that constitutes a significant financial interest; board memberships or other
employment; and/or ownership or rights in intellectual property that may be in conflict with the supplier’s
obligations to PATH. Suppliers and PATH are protected when actual or perceived conflicts of interest are
disclosed. When necessary, PATH will create a management plan that provides mitigation of potential
risks presented by the disclosed conflict of interest. Contacting third parties involved in the project, the
review panel, or any other party may be considered a conflict of interest and could result in
disqualification of the proposal. All communications regarding this solicitation shall be directed to
appropriate parties at PATH indicated in Section 4 A.
D. Acceptance
Acceptance of a proposal does not imply acceptance of its terms and conditions. PATH reserves the
option to negotiate on the final terms and conditions. We also reserve the right to negotiate the substance
of finalists’ proposals, as well as the option of accepting partial components of a proposal if appropriate.
E. Proposal validity
Proposals submitted under this request shall be valid for 90 days from the date the proposal is due. The
validity period shall be stated in the proposal submitted to PATH.
